{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:15:01Z","timestamp":1758629701412},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12185-015-1839-4","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T04:05:43Z","timestamp":1438661143000},"page":"335-341","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation"],"prefix":"10.1007","volume":"102","author":[{"given":"D.","family":"Kottwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"EL Hadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"El Amrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Dehbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nadifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdeladim","family":"Moumen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EL Hassan","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"1839_CR2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","volume":"315","author":"N Heisterkamp","year":"1985","unstructured":"Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Philadelphia translocation. Nature. 1985;315:758\u201361.","journal-title":"Nature"},{"key":"1839_CR3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079\u201382.","journal-title":"Science"},{"key":"1839_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF03041033","volume":"115","author":"C Sillaber","year":"2003","unstructured":"Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR, et al. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr. 2003;115:485\u2013504.","journal-title":"Wien Klin Wochenschr"},{"key":"1839_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattler","year":"2003","unstructured":"Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003;40:4\u201310.","journal-title":"Semin Hematol"},{"key":"1839_CR6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0140-6736(91)91706-Z","volume":"1337","author":"J Maurer","year":"1991","unstructured":"Maurer J, Janssen JWG, Thiel E, van Denderen J, Ludwig WD, Aydemir U, et al. Detection of chimeric BCR\/ABL genes in acute lymphoblastic leukemia by the polymerase chain reaction. Lancet. 1991;1337:1055\u20138.","journal-title":"Lancet"},{"key":"1839_CR7","first-page":"957","volume":"10","author":"S Schlieben","year":"1996","unstructured":"Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR\/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10:957\u201363.","journal-title":"Leukemia"},{"key":"1839_CR8","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V92.7.2315","volume":"92","author":"I Bu\u00f1o","year":"1998","unstructured":"Bu\u00f1o I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW, et al. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood. 1998;92:2315\u201321.","journal-title":"Blood"},{"key":"1839_CR9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursh S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome binding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and follow-up in CML: a study on 350 cases. Leukemia. 2002;16:53\u20139.","journal-title":"Leukemia"},{"key":"1839_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/gcc.1171","volume":"32","author":"YL Wang","year":"2001","unstructured":"Wang YL, Bagg A, Pear W, Nowell PC, Hess JL. Chronic myeloid leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer. 2001;32:97\u2013111.","journal-title":"Genes Chromosomes Cancer"},{"key":"1839_CR11","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwiseser D, Saglio G, Apperley J, et al. Chronic myloide leukemia: an update of concepts and management recommendations of European leukemia Net. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"1839_CR12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332.","journal-title":"N Engl J Med"},{"key":"1839_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"1839_CR14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gaber","year":"2003","unstructured":"Gaber J, Beillard E, Van Der Velden V, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of of \u2018real-time\u2019 quantitative reverse transciptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia. A Europe Against Cancer Program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"1839_CR15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.11172","volume":"92","author":"MC Muler","year":"2007","unstructured":"Muler MC, Saglio G, Lin F, Pfeifer H, Press RD, Tubbs RR, et al. An international study to standardize the detection and quantification of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica. 2007;92:970\u20133.","journal-title":"Haematologica"},{"key":"1839_CR16","first-page":"69","volume":"125","author":"S Bradford","year":"2006","unstructured":"Bradford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006;125:69\u201392.","journal-title":"Methods Mol Med"},{"key":"1839_CR17","unstructured":"National Comprehensive Cancer network. Clinical practice guideline in oncology: chronic myelogenous leukaemia, version 1. http\/\/nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf. Accessed July 2007, following the International Scale proposed previously."},{"key":"1839_CR18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"T Hughes","year":"2003","unstructured":"Hughes T, Kaeda J, Branford S, Rudzki Z, Hochhau A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332.","journal-title":"N Engl J Med"},{"key":"1839_CR19","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, Vander Velden V, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate controlgenes for diagnosis and residual disease detection in leukemia patients using \u2018real time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)- a European Against Cancer program. Leukemia. 2003;17:2474\u201386.","journal-title":"Leukemia"},{"issue":"12","key":"1839_CR20","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia. 2003;17(12):2318\u201357.","journal-title":"Leukemia"},{"key":"1839_CR21","unstructured":"Moumen A, Dehbi H, Kottwitz H, El Amrani M, H. El Hadi, H. Sefrioui. Comparison of real-time qPCR, conventional PCR and FISH in detecting Mbcr and mbcr translocation in Moroccan chronic myeloid leukaemia patients treated with Imatinib. GMR. 2014. (in press)."},{"issue":"2","key":"1839_CR22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","volume":"29","author":"H White","year":"2015","unstructured":"White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia. 2015;29(2):369\u201376. doi: 10.1038\/leu.2014.217 .","journal-title":"Leukemia"},{"issue":"8","key":"1839_CR23","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, M\u00fcller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330\u20138.","journal-title":"Blood"},{"issue":"4","key":"1839_CR24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"key":"1839_CR25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","volume":"115","author":"TI Mughal","year":"2001","unstructured":"Mughal TI, Yong A, Szydio RM, Dazzi F, Olavarria E, van Rhee F, et al. Molecular studies in patients with chronic myeloid leukemia in remission 5\u00a0years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol. 2001;115:569\u201374.","journal-title":"Br J Haematol"},{"key":"1839_CR26","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","volume":"107","author":"RD Press","year":"2006","unstructured":"Press RD, Love Z, Tronnes AA, Trant T, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107:4250\u20136.","journal-title":"Blood"},{"key":"1839_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V116.21.11.11","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuck P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantification of BCR-ABL mRNA. Blood. 2010;116:11\u2013117.","journal-title":"Blood"},{"key":"1839_CR28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/modpathol.3800026","volume":"17","author":"R Luthra","year":"2004","unstructured":"Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mol Pathol. 2004;17:96\u2013103.","journal-title":"Mol Pathol"},{"key":"1839_CR29","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with CML phase treated with imatinib mesylate. Clin Cancer. 2005;11:3425\u201332.","journal-title":"Clin Cancer"},{"issue":"8","key":"1839_CR30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","volume":"95","author":"F Cervantes","year":"2010","unstructured":"Cervantes F, L\u00f3pez-Garrido P, Montero MI, Jonte F, Mart\u00ednez J, Hern\u00e1ndez-Boluda JC, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica. 2010;95(8):1317\u201324.","journal-title":"Haematologica"},{"key":"1839_CR31","unstructured":"CLSI. Evaluation of precision performance of quantitative measurement methods: approved guidelines, 2nd. NCCLS document EP5-A2;2000."},{"key":"1839_CR32","unstructured":"Sefrioui H, El Amrani M and Kottwitz K. Patent WO2014042497A1: www.google.com\/patents\/WO2014042497A1?cl=en&hl=fr ."},{"key":"1839_CR33","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/bcj.2011.10","volume":"1","author":"JT Brown","year":"2011","unstructured":"Brown JT, Laosinchai-Wolf W, Hedges JB, Watt CD, Van Deerlin VM, Fletcher L, et al. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR\u2013ABL1 on the international reporting scale. Blood Cancer J. 2011;1:e13. doi: 10.1038\/bcj.2011.10 .","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1839-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1839-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T20:54:41Z","timestamp":1599425681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1839-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1839-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}